Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03907176 · ClinicalTrials.gov registry record · Phase 3

Study of Post-Herniorrhaphy Non-opioid MMA Regimens

A Phase 3 study, sponsored by Heron Therapeutics.

Completed
Registry status
Phase 3
Development phase
209
Enrollment target

NCT03907176: Completed Phase 3 study, sponsored by Heron Therapeutics.

NCT03907176 is a Phase 3 study that has completed, run by Heron Therapeutics. The registered enrollment target is 209 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03907176, a Phase 3 study, has completed, sponsored by Heron Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
209 participants
Enrollment target

Study Summary

This is a Phase 3b, open-label study to assess postoperative opioid use in subjects undergoing unilateral open inguinal herniorrhaphy with intraoperative administration of HTX-011 and a postoperative non-opioid multimodal analgesic (MMA) regimen. The study will be conducted in 2 sequential parts: Part 1 is randomized and Part 2 is Investigator's preference for MMA regimen.

Interventions

  • DRUG Acetaminophen
  • DRUG Ibuprofen
  • DRUG HTX-011
  • DEVICE Luer lock applicator

Trial Details

FieldValue
Enrollment Target 209 participants
Start Date 2019-04-04
Est. Completion 2021-11-22
Phase Phase 3
Heron Therapeutics

23 total trials

What the finished NCT03907176 record still lists

NCT03907176 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 4 interventions - of which Acetaminophen is the first listed.

NCT03907176 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03907176 about?

NCT03907176 is a clinical study titled "Study of Post-Herniorrhaphy Non-opioid MMA Regimens". This is a Phase 3b, open-label study to assess postoperative opioid use in subjects undergoing unilateral open inguinal herniorrhaphy with intraoperative administration of HTX-011 and a postoperative non-opioid multimodal analgesic (MMA) regimen. The study will be conducted in 2 sequential parts: Pa...

What is the current status of trial NCT03907176?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 209 participants. The study started on 2019-04-04. Estimated completion is 2021-11-22.

What interventions are being tested in trial NCT03907176?

The interventions under investigation include: Acetaminophen (DRUG), Ibuprofen (DRUG), HTX-011 (DRUG), Luer lock applicator (DEVICE).

Who is sponsoring clinical trial NCT03907176?

This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03907176's enrollment target sits among peer trials

209 1345th of 2000 higher than 656 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04742634 · 209 participants · Phase 1

    Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

  • NCT07214688 · 209 participants · Phase 2

    Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03907176, the US trial registry maintained by the National Library of Medicine. NCT03907176 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.